Radiopharm Therapeutics

Radiopharm Therapeutics is a clinical-stage biopharmaceutical company focused on developing a world-class platform of radiopharmaceutical products for diagnostic and therapeutic applications in oncology. The company's diverse pipeline targets high unmet medical needs, including brain, pancreatic, lung, and breast cancers. Radiopharm utilizes a variety of technology platforms, such as Nano-mAbs and PTPRZ1, to deliver radioisotopes directly to cancer cells with high precision. Headquartered in Australia and listed on the ASX, the company collaborates with leading global institutions like MD Anderson Cancer Center to advance its multi-modality portfolio. Its strategy involves a theranostic approach, combining diagnostic imaging with targeted radiotherapy.